## Highlights of This Issue 6645

### SPECIAL FEATURES

**CCR Translations**

6647  
The Context of Blood Vessels and Response to VEGF-Targeted Therapy  
Brian I. Rini  
*See related article, p. 6943*

### CCR Perspectives in Drug Approval

6650  
Abiraterone Acetate in Combination with Prednisone for the Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer: U.S. Food and Drug Administration Drug Approval Summary  
Paul G. Khutez, Yang-Min Ning, V. Ellen Mahler, Lijun Zhang, Shenghui Tang, Nitin Mehrotra, Amy Tiley, and Richard Pazdur

### CCR Drug Updates

6657  
Pralatrexate Pharmacology and Clinical Development  
Enrica Marchi, Michael Mangone, Kelly Zullo, and Owen A. O’Connor

### Molecular Pathways

6662  
Molecular Pathways: Targeting MALT1 Paracaspase Activity in Lymphoma  
Lorena Fontán and Ari Melnick

### Perspectives

6669  
Anticipating the Clinical Use of Prognostic Gene Expression–Based Tests for Colon Cancer Stage II and III: Is Godot Finally Arriving?  
Anita Sveen, Arild Nesbakken, Trude H. Aagesen, Marianne G. Guren, Kjell M. Tveit, Bølf L. Skotheim, and Ragnar Al. Lothe

## Review

6678  
Hepatocellular Carcinoma from an Immunologic Perspective  
Tim F. Greten, Austin G. Duffy, and Firouzeh Korangy

## HUMAN CANCER BIOLOGY

6686  
Poor Concordance among Nine Immunohistochemistry Classifiers of Cell-of-Origin for Diffuse Large B-Cell Lymphoma: Implications for Therapeutic Strategies  
Rita Coutinho, Andrew James Clear, Andrew Owen, Andrew Wilson, Janet Matthews, Abigail Lee, Rute Alvarez, Maria Gomes da Silva, José Cabeças, Maria Calaminici, and John G. Gribben

### BRAF Fusions Define a Distinct Molecular Subset of Melanomas with Potential Sensitivity to MEK Inhibition  

### HAb18G/CD147 Promotes pSTAT3-Mediated Pancreatic Cancer Development via CD44s  
Ling Li, Wenhua Tang, Xiaoqing Wu, David Karnak, Xiaoqie Meng, Rachel Thompson, Xinbao Hao, Yongmin Li, Xiaotan T. Qiao, Jiayuh Lin, James Fuchs, Diane M. Simeone, Zhi-Nan Chen, Theodore S. Lawrence, and Liang Xu

## CANCER THERAPY: PRECLINICAL

6716  
Development, Characterization, and Reversal of Acquired Resistance to the MEK1 Inhibitor Selumetinib (AZD6244) in an In Vivo Model of Childhood Astrocytoma  
Hemant K. Bid, Aaron Kibler, Doris A. Phelps, Saggyberek Manap, Linlin Xiao, Jiayuh Lin, David Capper, Duane Oswald, Brian Geier, Mariko DeWire, Paul D. Smith, Raushan T. Kurmasheva, Xiaokui Mo, Soledad Fernandez, and Peter J. Houghton
<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>6730</td>
<td>Ang-2-VEGF-A CrossMab, a Novel Bispecific Human IgG1 Antibody Blocking VEGF-A and Ang-2 Functions Simultaneously, Mediates Potent Antitumor, Antiangiogenic, and Antimetastatic Efficacy</td>
<td>Yvonne Kienast, Christian Klein, Werner Scheuer, Romi Raemisch, Erica Lorenzon, Dirk Bernicke, Frank Herting, Sidney Yu, Huynh Hung The, Laurent Martarelo, Christian Gassner, Kay-Gunnar Stubenrauch, Kate Munro, Hellmut G. Augustin, and Markus Thomas</td>
</tr>
<tr>
<td>6741</td>
<td>Reprogramming Metabolism with Metformin Improves Tumor Oxygenation and Radiotherapy Response</td>
<td>Vanessa E. Zannella, Alan Dal Pra, Hala Muaddi, Trevor D. McKee, Shawn Stapleton, Jenna Sykes, Rachel Glicksman, Selim Chaib, Paul Zamiara, Michael Milesevic, Bradly G. Wouters, Robert G. Bristow, and Marianne Koritzinsky</td>
</tr>
<tr>
<td>6751</td>
<td>Increased TGF-α as a Mechanism of Acquired Resistance to the Anti-EGFR Inhibitor Cetuximab through EGFR–MET Interaction and Activation of MET Signaling in Colon Cancer Cells</td>
<td>Teresa Troiani, Erika Martinelli, Stefania Napolitano, Donata Vitagliano, Loreta Pia Ciaffreda, Sara Costantino, Floriania Morgillo, Anna Capasso, Vincenzo Sforza, Anna Nappi, Raffaele De Palma, Elena D'Aiuto, Liberato Berrino, Roberto Bianco, and Fortunato Ciardiello</td>
</tr>
<tr>
<td>6766</td>
<td>Use of the Proton Pump Inhibitor Pantoprazole to Modify the Distribution and Activity of Doxorubicin: A Potential Strategy to Improve the Therapy of Solid Tumors</td>
<td>Krupa J. Patel, Carol Lee, Qian Tan, and Ian F. Tannock</td>
</tr>
<tr>
<td>6777</td>
<td>The Janus Kinases Inhibitor AZD1480 Attenuates Growth of Small Cell Lung Cancers In Vitro and In Vivo</td>
<td>Jih-Hsiang Lee, Kang-Seo Park, Anna Teresa Alberobello, Bhaskar Kallakury, Meng-Tzu Weng, Yisong Wang, and Giuseppe Giaccone</td>
</tr>
<tr>
<td>6802</td>
<td>Monoclonal Antibody against Cell Surface GRP78 as a Novel Agent in Suppressing P13K/AKT Signaling, Tumor Growth, and Metastasis</td>
<td>Ren Liu, Xiaqing Li, Wenming Guo, Yue Zhou, Shuan Wei, Satyajit K. Mitra, Valery Krasnoperov, Dezhen Dong, Shuanglong Liu, Dan Li, Genyuan Zhu, Stan Louie, Peter S. Conti, Zibo Li, Amy S. Lee, and Parkash S. Gill</td>
</tr>
</tbody>
</table>

**IMAGING, DIAGNOSIS, PROGNOSIS**

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>6820</td>
<td>A Novel Engineered Anti-CD20 Tracer Enables Early Time PET Imaging in a Humanized Transgenic Mouse Model of B-cell Non-Hodgkins Lymphoma</td>
<td>Arutselvan Natarajan, Benjamin J. Hackel, and Sanjiv Sam Gambhir</td>
</tr>
<tr>
<td>6842</td>
<td>Epigenetic Inactivation of microRNA-34b/c Predicts Poor Disease-Free Survival in Early-Stage Lung Adenocarcinoma</td>
<td>Ernest Nadal, Guoan Chen, Marc Gallegos, Lin Lin, Daysha Ferrer-Torres, Anna Trini, Zhuwen Wang, Jules Lin, Rishindra M. Reddy, Roger Llatjos, Ignacio Escobar, Juan Moya, Andrew C. Chang, Felipe Cardenal, Gabriel Capella, and David G. Beer</td>
</tr>
</tbody>
</table>
The Residual Tumor Autophagy Marker LC3B Serves as a Prognostic Marker in Local Advanced Breast Cancer after Neoadjuvant Chemotherapy
Sheng Chen, Yi-Zhou Jiang, Liang Huang, Ruo-Ji Zhou, Ke-Da Yu, Yin Liu, and Zhi-Ming Shao

CANCER THERAPY: CLINICAL

Comparative Efficacy of Bisphosphonates in Metastatic Breast and Prostate Cancer and Multiple Myeloma: A Mixed-Treatment Meta-analysis
Carlo Palmieri, John R. Fullarton, and Janet Brown

Cladribine with Immediate Rituximab for the Treatment of Patients with Variant Hairy Cell Leukemia
Robert J. Kreitman, Wyndham Wilson, Katherine R. Calvo, Evgeny Arons, Laura Roth, Jeffrey Sapolsky, Hong Zhou, Mark Raffeld, and Maryalice Stetler-Stevenson

Phase I Study of Panobinostat plus Everolimus in Patients with Relapsed or Refractory Lymphoma
Yasuhiro Oki, Daniela Buglio, Michelle Fanale, Luis Fayad, Amanda Copeland, Jorge Romaguera, Larry W. Kwan, Barbara Pro, Silvana de Castro Faria, Sattva Neelapu, Nathan Fowler, Fredrick Hagemeister, Jie Xin Zhang, Shouhao Zhou, Lei Feng, and Anas Younes

Long-term Survival and Biomarker Correlates of Tasquinimod Efficacy in a Multicenter Randomized Study of Men with Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer

Phase I Trial of Preoperative Chemoradiation plus Sorafenib for High-Risk Extremity Soft Tissue Sarcomas with Dynamic Contrast-Enhanced MRI Correlates

PREDICTIVE BIOMARKERS AND PERSONALIZED MEDICINE

Loss of NAPRT1 Expression by Tumor-Specific Promoter Methylation Provides a Novel Predictive Biomarker for NAMPT Inhibitors
David S. Shames, Kristi Elkins, Kimberly Walter, Thomas Holcomb, Pan Du, Dane Mohl, Yang Xiao, Thinh Pham, Peter M. Haverty, Bianca Liederer, Xiaorong Liang, Robert L. Vauch, Thomas O’Brien, Richard Bourgon, Hartmut Koeppe, and Lisa D. Belmont

The Effect of VEGF-Targeted Therapy on Biomarker Expression in Sequential Tissue from Patients with Metastatic Clear Cell Renal Cancer

Large-scale Analysis of PDGFRA Mutations in Melanomas and Evaluation of Their Sensitivity to Tyrosine Kinase Inhibitors Imatinib and Crenolanib
Jie Dai, Yan Kong, Lu Si, Zhu Hong Chi, Chuanliang Cui, Xinan Sheng, Lili Mao, Siming Li, Bin Lian, Ruifeng Yang, Shujing Liu, Xiaowei Xu, and Jun Guo

Tumor Stromal Architecture Can Define the Intrinsic Tumor Response to VEGF-Targeted Therapy
See related article, p. 6647

Prognostic and Predictive Blood-Based Biomarkers in Patients with Advanced Pancreatic Cancer: Results from CALGB80303 (Alliance)
Andrew B. Nixon, Herbert Pang, Mark D. Starr, Paula N. Friedman, Monica M. Bertagnolli, Heddy L. Kindler, Richard M. Goldberg, Alan P. Venook, and Herbert I. Hurwitz for the Alliance for Clinical Trials In Oncology
Comprehensive Biomarker Analysis and Final Efficacy Results of Sorafenib in the BATTLE Trial


Evaluation and Clinical Analyses of Downstream Targets of the Akt Inhibitor GDC-0068

Yibing Yan, Violeta Serra, Ludmila Prudkin, Maurizio Scaltriti, Sumati Murli, Olga Rodriguez, Marta Guzman, Deepak Sampath, Michelle Nannini, Yuanyuan Xiao, Marie-Claire Wagle, Jenny Q. Wu, Matthew Wongchenko, Garret Hampton, Vanitha Ramakrishnan, Mark R. Lackner, Cristina Saura, Desamparados Roda, Andres Cervantes, Josep Tabernero, Premal Patel, and Jose Baselga

Acknowledgment to Reviewers

ABOUT THE COVER

The cover shows drug distribution in a solid tumor derived from breast cancer cells in a mouse xenograft. Immunohistochemical staining shows enhanced doxorubicin distribution around functional blood vessels in mice pretreated with pantoprazole. For details, see the article by Patel and colleagues on page 6766 of this issue.